Effects of Indacaterol via EPIC and Concept1 compared to placebo

• Research type

  Research Study

• Full title

  A randomized, double-blind, double-dummy, placebo-controlled, 3-period crossover study to evaluate the pharmacodynamics, pharmacokinetics, safety and tolerability of orally inhaled indacaterol administered via the EPIC test fixture and the Concept1 device in adult patients with persistent asthma.

• IRAS ID

  124777

• Contact name

  Dave Singh

• Contact email

  dsingh@meu.org.uk

• Sponsor organisation

  Novartis Pharmaceuticals UK Limited

• Eudract number

  2011-001824-39

• REC name

  North West - Greater Manchester Central Research Ethics Committee

• REC reference

  13/NW/0209

• Date of REC Opinion

  12 Apr 2013

• REC opinion

  Favourable Opinion